Lilly’s Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial
Eli Lilly And Co (NYSE:LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib)…
Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021
Cullinan Oncology (CGEM) - https://www.globenewswire.com/news-release/2021/05/19/2232874/0/en/Cullinan-Oncology-to-Provide-CLN-081-Clinical-Update-at-ASCO-2021.html
BeiGene (BGNE)
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 11)
Earnings Scheduled For May 4, 2021
Companies Reporting Before The Bell
• Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million.
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.
Eli Lilly And Incyte Announce Baricitinib Improved Hair Regrowth For Alopecia Areata Patients In Second Phase 3 Study
Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today results from a second Phase 3 trial (BRAVE-AA1) evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe